Last reviewed · How we verify
Cozaar (LOSARTAN POTASSIUM)
Cozaar (generic name: LOSARTAN POTASSIUM) is a Angiotensin 2 Receptor Blocker Small molecule drug developed by Merck & Co.. It is currently FDA-approved (first approved 1995) for Diabetic renal disease, Hypertension with Left Ventricular Hypertrophy, Hypertensive disorder.
Cozaar works by blocking the action of angiotensin II on its receptor, which helps to relax blood vessels and lower blood pressure.
Cozaar, also known as losartan, is used to prevent cardiovascular disease and has been studied for its potential to prevent paclitaxel-induced peripheral neuropathy in breast cancer patients. It has also been studied for its effects on conditions such as chronic kidney disease, rheumatoid arthritis, and diabetes mellitus.
At a glance
| Generic name | LOSARTAN POTASSIUM |
|---|---|
| Sponsor | Merck & Co. |
| Drug class | Angiotensin 2 Receptor Blocker |
| Target | Type-1 angiotensin II receptor |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1995 |
Mechanism of action
Mechanism of ActionAngiotensin II [formed from angiotensin in reaction catalyzed by angiotensin converting enzyme (ACE, kininase II)], is potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system and an important component in the pathophysiology of hypertension. It also stimulates aldosterone secretion by the adrenal cortex. Losartan and its principal active metabolite block the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor found in many tissues (e.g., vascular smooth muscle, adrenal gland). There is also an AT2 receptor found in many tissues but it is not known to be associated with cardiovascular homeostasis. Both losartan and its principal active metabolite do not exhibit any partial agonist activity at the AT1 receptor and have much greater affinity (about 1000-fold) for the AT1 receptor than for the AT2 receptor. In vitro binding studies indicate that losart
Approved indications
- Diabetic renal disease
- Hypertension with Left Ventricular Hypertrophy
- Hypertensive disorder
- Hypertensive urgency
Boxed warnings
- WARNING: FETAL TOXICITY When pregnancy is detected, discontinue losartan potassium as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1) ]. WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue losartan potassium as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. (5.1)
Common side effects
- Pemphigus
- Synovitis
- Hand deformity
- Systemic lupus erythematosus
- Contraindicated product administered
- Maternal exposure during pregnancy
- Treatment failure
- Infusion related reaction
- Glossodynia
- Cardiac failure congestive
- Dizziness
- Wound
Drug interactions
- rifampicin
- spironolactone
- triamterene
Key clinical trials
- The Effect of Losartan on Cephalexin (PHASE1)
- Losartan for Diffuse Myocardial Fibrosis in Sickle Cell Disease (PHASE2)
- Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma (PHASE1)
- Losartan for Corneal Fibrosis (NA)
- Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (PHASE4)
- Drug Interaction Study of ZYN002 Transdermal Gel and Probe Substrates (PHASE1)
- Losartan + Sunitinib in Treatment of Osteosarcoma (PHASE1)
- The COVID-RASi Trial (COVID-19) (PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
| 12156869 | 2041-10-07 | Formulation |
| 11890273 | 2041-10-07 | Formulation |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cozaar CI brief — competitive landscape report
- Cozaar updates RSS · CI watch RSS
- Merck & Co. portfolio CI
Frequently asked questions about Cozaar
What is Cozaar?
How does Cozaar work?
What is Cozaar used for?
Who makes Cozaar?
What is the generic name of Cozaar?
What drug class is Cozaar in?
When was Cozaar approved?
What development phase is Cozaar in?
What are the side effects of Cozaar?
What does Cozaar target?
Related
- Drug class: All Angiotensin 2 Receptor Blocker drugs
- Target: All drugs targeting Type-1 angiotensin II receptor
- Manufacturer: Merck & Co. — full pipeline
- Therapeutic area: All drugs in Metabolic
- Indication: Drugs for Diabetic renal disease
- Indication: Drugs for Hypertension with Left Ventricular Hypertrophy
- Indication: Drugs for Hypertensive disorder
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing